PDCD1 and acute myeloid leukemia: A recent phase 2 trial of R/R AML patients receiving pembrolizumab, a PD-1 inhibitor, with HiDAC demonstrated promising clinical activity in TP53mut patients, reporting a CR rate of 40% [98].